The continuing HIV vaccine saga: is a paradigm shift necessary?

Smith, Kendall A.
January 2006
Medical Immunology;2006, Vol. 5, p1
Academic Journal
As pointed out in previous editorials, the development of an effective vaccine for the Human Immunodeficiency Virus capable of preventing infection, or even one capable of preventing the Acquired Immunodeficiency Disease Syndrome, has eluded investigators for the past 20 years. Now Reche and Keskin and their co-workers have provided evidence that an entirely new approach, based upon modern bioinformatics methods and skillful in vitro immunological experiments, may result in an effective way to prime the T cell immune response of normal individuals against conserved peptide epitopes.


Related Articles

  • AIDS Vaccine A 20-Year Effort. Gard, Carolyn // Current Health 2;Dec2001, Vol. 28 Issue 4, p18 

    Reports the effort of researchers for finding AIDS vaccine in the United States. Definition of AIDS; Description of HIV; Destruction of T cells in the body by HIV.

  • AIDS vaccine.  // Newsweek (Atlantic Edition);06/15/98 (Atlantic Edition), Vol. 131 Issue 24, p3 

    Notes the June 1998 approval by the United States Food and Drug Administration of a large-scale efficacy trial of an AIDS vaccine. Development of Aidsvax by the San Francisco, California company Vaxgen; Extent of the trial.

  • New HIV/AIDS vaccine shows promise. Townes, Glenn // New York Amsterdam News;10/1/2009, Vol. 100 Issue 40, p31 

    The article discusses the result of the study conducted by the U.S. Military HIV Research Program in Rockville, Maryland, which states that a new drug regimen designed to prevent HIV infection has shown critical success in fighting the illness. It mentions that the drug regimen involves a...

  • Scientific Approaches to AIDS Prevention and Control in China. Teng, T.; Shao, Y. // Advances in Dental Research;Apr2011, Vol. 23 Issue 1, p10 

    The HIV epidemic in China started among intravenous drug users in the late 1980s. The second wave of the epidemic was caused by an outbreak in the paid plasma donors in central China in the mid-1990s. Sexually transmitted HIV cases have steadily increased and comprised more than half the...

  • Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Gilchrist, F C; Bunn, C; Foley, P J; Lympany, P A; Black, C M; Welsh, K I; du Bois, R M // Genes & Immunity;Apr2001, Vol. 2 Issue 2, p76 

    Scleroderma is a condition of variable phenotype characterised by fibrosis of the skin and internal organs. There is a range of disease-specific autoantibodies found in the sera of patients. The aims of this study were to: (1) investigate the role of the MHC and particularly HLA-DP in the...

  • HLA Class I and Class II alleles and haplotypes in Mexican mestizos established from serological... de Leo, Claudia; Castelan, Natalia // Human Biology;Dec97, Vol. 69 Issue 6, p809 

    Presents a study in which information is presented on the frequency and association of class II antigens of the major histocompatibility complex in Mexicans. Description of the study; Predominant antigens; Most common halothane found.

  • Extensive MHC variability in cichlid fishes of lake Malawi. Klein, Dagmar; Ono, Hideki // Nature;7/22/1993, Vol. 364 Issue 6435, p330 

    Describes high sequence variability of class II major histocompatibility complex genes in a sample of Lake Malawi cichlids. Difference in ecology, behavior, and morphology; Molecular characteristics; Adaptive radiation; Use in estimating the size of the population that founded the species flock.

  • What to do with $88 million? Lett, Dan // CMAJ: Canadian Medical Association Journal;6/15/2010, Vol. 182 Issue 9, pE415 

    The article reports on the 88 million dollar allocation of the government of Canada intended for AIDS treatment and prevention. It says that there are speculations on how the government will use the amount. The Public Health Agency of Canada (PHAC) which monitors the Canadian HIV Vaccine...

  • NY leads search for AIDS vaccine. Scott, Gale // Crain's New York Business;8/21/2006, Vol. 22 Issue 34, p1 

    This article reports that clinical trials of several AIDS vaccines, including Merck & Co. Inc.'s AD-5 vaccine, are continuing at many major medical institutions in Manhattan, New York City. According to Beryl Koblin, head of the Laboratory of Infectious Disease Prevention for the New York Blood...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics